Therapeutic role of ursodeoxycholic acid in colitis-associated cancer via gut microbiota modulation

Therapeutic role of ursodeoxycholic acid in colitis-associated cancer via gut microbiota modulation
复制标题

熊去氧胆酸通过肠道微生物群调节对结肠炎相关癌症的治疗作用

DOI:
10.1016/j.ymthe.2022.10.014
复制
发表时间:
2022-10-29
期刊:
影响因子:
12.4
通讯作者:
Lan, Ping
Lan, Ping
中科院分区:
医学1区
文献类型:
--
作者:
He, Qilang;Wu, Jinjie;Ke, Jia;Zhang, Qiang;Zeng, Wanyi;Luo, Zhanhao;Gong, Junli;Chen, Yuan;He, Zhen;Lan, Ping

文献摘要

参考文献

相似文献

炎症性肠病(IBD)是结肠炎相关癌症(CAC)的诱发因素。胆汁酸与肠道微生物群之间的关联已在结肠肿瘤中得到证实。然而,熊去氧胆酸 (UDCA) 对结肠炎和 CAC 发展过程中肠道微生物群改变的影响尚不清楚。我们对公开数据集的分析证明了 UDCA 治疗与阿克曼氏菌积累之间的关联。 UDCA 介导的 DSS 诱导的结肠炎的缓解是微生物依赖性的。 UDCA 治疗显着上调小鼠模型中阿克曼氏菌的定植。 Akkermansia 的定植与 UDCA 治疗后粘液层的增强以及巨噬细胞中胆汁酸受体的激活有关。 UDCA 通过下调炎症和 Akkermansia 的积累,在 AOM-DSS 和 ApcMin/+-DSS 模型中的 CAC 预防和治疗中发挥作用。这项研究表明,UDCA 干预可以重塑肠道稳态,促进阿克曼​​氏菌定植,预防和治疗结肠炎和 CAC。他等人。表明熊去氧胆酸(UDCA)以微生物依赖性方式在结肠炎中发挥保护作用。具体来说,UDCA 治疗可以通过增强粘液层来重塑肠道稳态,从而促进阿克曼​​氏菌的积累。 UDCA 治疗还可以通过肠道微生物群调节来预防和治疗结肠炎相关癌症 (CAC)。
Inflammatory bowel disease (IBD) is a predisposing factor for colitis-associated cancer (CAC). The association between bile acids and the gut microbiota has been demonstrated in colon neoplasia; however, the effect of ursodeoxycholic acid (UDCA) on gut microbiota alteration in development of colitis and CAC is unknown. Our analysis of publicly available datasets demonstrated the association of UDCA treatment and accumulation of Akkermansia. UDCA-mediated alleviation of DSS-induced colitis was microbially dependent. UDCA treatment significantly upregulated Akkermansia colonization in a mouse model. Colonization of Akkermansia was associated with enhancement of the mucus layer upon UDCA treatment as well as activation of bile acid receptors in macrophages. UDCA played a role in CAC prevention and treatment in the AOM-DSS and ApcMin/+-DSS models through downregulation of inflammation and accumulation of Akkermansia. This study suggests that UDCA intervention could reshape intestinal gut homeostasis, facilitating colonization of Akkermansia and preventing and treating colitis and CAC. He et al. suggest a protective role of ursodeoxycholic acid (UDCA) in colitis in a microbially dependent manner. Specifically, UDCA treatment could reshape gut homeostasis by enhancing the mucus layer, thus promoting Akkermansia accumulation. UDCA treatment could also prevent and treat colitis-associated cancer (CAC) through gut microbiota modulation.
DOI: 10.1371/journal.pone.0181183
发表时间: 2017
期刊: PloS one
影响因子: 3.7
作者:
Kim EK;Cho JH;Kim E;Kim YJ
通讯作者: Kim YJ
DOI: 10.3389/fmicb.2017.01765
发表时间: 2017
影响因子: 5.2
作者:
Cani PD;de Vos WM
通讯作者: de Vos WM
DOI: 10.1016/j.apsb.2015.01.004
发表时间: 2015-03
期刊: Acta pharmaceutica Sinica. B
影响因子: --
作者:
Ding L;Yang L;Wang Z;Huang W
通讯作者: Huang W
DOI: 10.1080/19490976.2019.1589281
发表时间: 2019-11-02
期刊: GUT MICROBES
影响因子: 12.2
作者:
Jang, You Jin;Kim, Woon-Ki;Ko, Gwangpyo
通讯作者: Ko, Gwangpyo
DOI: 10.1073/pnas.1219451110
发表时间: 2013-05-28
影响因子: 11.1
作者:
Everard, Amandine;Belzer, Clara;Cani, Patrice D.
通讯作者: Cani, Patrice D.